Liabilities, Current of Y-mAbs Therapeutics, Inc. from 31 Dec 2017 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Summary
Y-mAbs Therapeutics, Inc. quarterly Liabilities, Current in USD history and change rate from 31 Dec 2017 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Liabilities, Current for the quarter ending 30 Jun 2025 was $22,945,000, a 47% decline year-over-year.
Source SEC data
View on sec.gov
Liabilities, Current, Quarterly (USD)
Liabilities, Current, YoY Quarterly Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $22,945,000 -$20,525,000 -47% 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $18,957,000 +$1,352,000 +7.7% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $23,698,000 +$3,570,000 +18% 31 Dec 2024 10-Q 08 Aug 2025 2025 Q2
Q3 2024 $25,292,000 +$3,480,000 +16% 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $43,470,000 +$19,237,000 +79% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $17,605,000 -$8,315,000 -32% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $20,128,000 -$8,156,000 -29% 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $21,812,000 -$10,203,000 -32% 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $24,233,000 -$5,217,000 -18% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $25,920,000 -$3,122,000 -11% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $28,284,000 +$409,000 +1.5% 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $32,015,000 +$6,656,000 +26% 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $29,450,000 +$8,464,000 +40% 30 Jun 2022 10-Q 08 Aug 2022 2021 Q3
Q1 2022 $29,042,000 +$12,042,000 +71% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $27,875,000 +$8,340,000 +43% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $25,359,000 +$5,582,000 +28% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $20,986,000 +$5,279,000 +34% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $17,000,000 +$2,157,000 +15% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $19,535,000 +$5,949,000 +44% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $19,777,000 +$5,785,000 +41% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $15,707,000 +$2,079,000 +15% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $14,843,000 +$4,542,000 +44% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $13,586,000 +$4,463,000 +49% 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $13,992,000 +$4,676,000 +50% 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q2 2019 $13,628,000 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $10,301,000 31 Mar 2019 10-Q 10 May 2019 2019 Q1
Q4 2018 $9,123,000 +$1,198,000 +15% 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $9,316,000 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q4 2017 $7,925,000 31 Dec 2017 10-K 22 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.